BridgeBio Pharma, Inc. Restructuring Charges
BridgeBio Pharma, Inc. (BBIO) reported Restructuring Charges of $15.61 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2025-02-20
- BridgeBio Pharma, Inc. restructuring charges for the quarter ending 2024-12-31 was $4.69M, a 522.41% increase year-over-year.
- BridgeBio Pharma, Inc. restructuring charges for the quarter ending 2024-09-30 was $4.62M, a 1598.90% increase year-over-year.
- BridgeBio Pharma, Inc. restructuring charges for the quarter ending 2024-06-30 was $2.89M, a 18.13% decline year-over-year.
- BridgeBio Pharma, Inc. restructuring charges for the quarter ending 2024-03-31 was $3.40M, a 0.92% increase year-over-year.
- BridgeBio Pharma, Inc. restructuring charges for fiscal 2024 was $15.61M, a 96.88% increase from fiscal 2023.
- BridgeBio Pharma, Inc. restructuring charges for fiscal 2023 was $7.93M, a 81.89% decline from fiscal 2022.
- BridgeBio Pharma, Inc. restructuring charges for fiscal 2022 was $43.77M.
- BridgeBio Pharma, Inc. restructuring charges for fiscal 2021 was $0.00.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2024-12-31 | $4.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $9.31M derived: sum of 2 quarters · filed 2025-02-20 | $12.21M derived: sum of 3 quarters · filed 2025-02-20 | $15.61M 10-K · filed 2025-02-20 |
| 2024-09-30 | $4.62M 10-Q · filed 2024-11-12 | $7.51M derived: sum of 2 quarters · filed 2024-11-12 | $10.91M 10-Q · filed 2024-11-12 | $11.67M derived: sum of 4 quarters · filed 2025-02-20 |
| 2024-06-30 | $2.89M 10-Q · filed 2024-08-01 | $6.29M 10-Q · filed 2024-08-01 | $7.04M derived: sum of 3 quarters · filed 2025-02-20 | $7.32M derived: sum of 4 quarters · filed 2025-02-20 |
| 2024-03-31 | $3.40M 10-Q · filed 2024-05-02 | $4.15M derived: sum of 2 quarters · filed 2025-02-20 | $4.43M derived: sum of 3 quarters · filed 2025-02-20 | $7.96M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-12-31 | $754.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $1.03M derived: sum of 2 quarters · filed 2025-02-20 | $4.56M derived: sum of 3 quarters · filed 2025-02-20 | $7.93M 10-K · filed 2025-02-20 |
| 2023-09-30 | $272.00K 10-Q · filed 2024-11-12 | $3.80M derived: sum of 2 quarters · filed 2024-11-12 | $7.17M 10-Q · filed 2024-11-12 | $14.86M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $3.53M 10-Q · filed 2024-08-01 | $6.90M 10-Q · filed 2024-08-01 | $14.59M derived: sum of 3 quarters · filed 2025-02-20 | $19.61M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $3.37M 10-Q · filed 2024-05-02 | $11.06M derived: sum of 2 quarters · filed 2025-02-20 | $16.08M derived: sum of 3 quarters · filed 2025-02-20 | $24.47M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $7.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $12.71M derived: sum of 2 quarters · filed 2025-02-20 | $21.10M derived: sum of 3 quarters · filed 2025-02-20 | $43.77M 10-K · filed 2025-02-20 |
| 2022-09-30 | $5.02M 10-Q · filed 2023-11-02 | $13.41M derived: sum of 2 quarters · filed 2023-11-02 | $36.07M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $8.40M 10-Q · filed 2023-08-03 | $31.06M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $22.66M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |